Prospective surveillance for Pseudomonas aeruginosa cross-infection at a cystic fibrosis center.

PubWeight™: 1.20‹?› | Rank: Top 10%

🔗 View Article (PMID 15542795)

Published in Am J Respir Crit Care Med on November 12, 2004

Authors

Andrew M Jones1, Mary E Dodd, John R W Govan, Catherine J Doherty, Catherine M Smith, Barbara J Isalska, A Kevin Webb

Author Affiliations

1: Adult Cystic Fibrosis Centre, Department of Medical Microbiology, Wythenshawe Hospital, South Manchester University Hospitals NHS Trust, Southmoor Road, Manchester M23 9LT, UK. andmarkj@hotmail.com

Articles citing this

Clinical significance of microbial infection and adaptation in cystic fibrosis. Clin Microbiol Rev (2011) 2.23

Viability of Pseudomonas aeruginosa in cough aerosols generated by persons with cystic fibrosis. Thorax (2014) 1.57

Pseudomonas aeruginosa genotype prevalence in Dutch cystic fibrosis patients and age dependency of colonization by various P. aeruginosa sequence types. J Clin Microbiol (2009) 1.21

Pseudomonas aeruginosa exhibits frequent recombination, but only a limited association between genotype and ecological setting. PLoS One (2012) 1.17

Diagnostic and prognostic value of serum antibodies against Pseudomonas aeruginosa in cystic fibrosis. Thorax (2006) 1.01

Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium. Science (2016) 0.89

Update in cystic fibrosis 2005. Am J Respir Crit Care Med (2006) 0.86

Pseudomonas aeruginosa in children with cystic fibrosis diagnosed through newborn screening: assessment of clinic exposures and microbial genotypes. Pediatr Pulmonol (2010) 0.83

Segregation is good for patients with cystic fibrosis. J R Soc Med (2008) 0.77

High Pseudomonas aeruginosa acquisition rate in CF. Thorax (2006) 0.76

Infection control knowledge, beliefs and behaviours amongst cystic fibrosis patients with epidemic Pseudomonas aeruginosa. BMC Pulm Med (2015) 0.76

Segregation is not good for patients with cystic fibrosis. J R Soc Med (2008) 0.75

The Effect of Strict Segregation on Pseudomonas aeruginosa in Cystic Fibrosis Patients. PLoS One (2016) 0.75

Articles by these authors

A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med (2010) 2.72

Burkholderia cenocepacia sp. nov.--a new twist to an old story. Res Microbiol (2003) 2.49

Vitamin-D deficiency is associated with chronic bacterial colonisation and disease severity in bronchiectasis. Thorax (2012) 2.18

Identification of severe acute respiratory syndrome coronavirus replicase products and characterization of papain-like protease activity. J Virol (2004) 1.97

Diagnostic importance of pulmonary interleukin-1beta and interleukin-8 in ventilator-associated pneumonia. Thorax (2009) 1.87

Burkholderia anthina sp. nov. and Burkholderia pyrrocinia, two additional Burkholderia cepacia complex bacteria, may confound results of new molecular diagnostic tools. FEMS Immunol Med Microbiol (2002) 1.86

Updated version of the Burkholderia cepacia complex experimental strain panel. J Clin Microbiol (2003) 1.74

End-organ dysfunction in cystic fibrosis: association with angiotensin I converting enzyme and cytokine gene polymorphisms. Am J Respir Crit Care Med (2003) 1.52

Plant host and sugar alcohol induced exopolysaccharide biosynthesis in the Burkholderia cepacia complex. Microbiology (2008) 1.48

IgE-mediated immune responses and airway detection of Aspergillus and Candida in adult cystic fibrosis. Chest (2013) 1.46

Influence of taxonomic status on the in vitro antimicrobial susceptibility of the Burkholderia cepacia complex. J Antimicrob Chemother (2002) 1.38

A putative gene cluster for aminoarabinose biosynthesis is essential for Burkholderia cenocepacia viability. J Bacteriol (2007) 1.31

Analysis and separation of residues important for the chemoattractant and antimicrobial activities of beta-defensin 3. J Biol Chem (2008) 1.28

Associations between clinical variables and quality of life in adults with cystic fibrosis. J Cyst Fibros (2005) 1.20

Hypermutability in environmental Pseudomonas aeruginosa and in populations causing pulmonary infection in individuals with cystic fibrosis. Microbiology (2007) 1.13

Structure-activity relationships in defensin dimers: a novel link between beta-defensin tertiary structure and antimicrobial activity. J Biol Chem (2004) 1.10

Identification of DNA markers for a transmissible Pseudomonas aeruginosa cystic fibrosis strain. Am J Respir Cell Mol Biol (2005) 0.98

Contributions of two UDP-glucose dehydrogenases to viability and polymyxin B resistance of Burkholderia cenocepacia. Microbiology (2009) 0.98

Can health-related quality of life predict survival in adults with cystic fibrosis? Am J Respir Crit Care Med (2008) 0.97

Lysogeny and bacteriophage host range within the Burkholderia cepacia complex. J Med Microbiol (2003) 0.96

The heart in cystic fibrosis. J R Soc Med (2002) 0.96

Clinical outcome for cystic fibrosis patients infected with transmissible pseudomonas aeruginosa: an 8-year prospective study. Chest (2010) 0.96

Pseudomonas aeruginosa cross-infection in cystic fibrosis. Lancet (2002) 0.95

Incidence and clinical impact of respiratory viruses in adults with cystic fibrosis. Thorax (2013) 0.95

The human cathelicidin LL-37 preferentially promotes apoptosis of infected airway epithelium. Am J Respir Cell Mol Biol (2010) 0.93

Intravenous antibiotics reduce the presence of Aspergillus in adult cystic fibrosis sputum. Thorax (2013) 0.92

Trappin-2 promotes early clearance of Pseudomonas aeruginosa through CD14-dependent macrophage activation and neutrophil recruitment. Am J Pathol (2009) 0.92

Subdivision of the bacterioferritin comigratory protein family of bacterial peroxiredoxins based on catalytic activity. Biochemistry (2010) 0.89

Covalent dimer species of beta-defensin Defr1 display potent antimicrobial activity against multidrug-resistant bacterial pathogens. Antimicrob Agents Chemother (2007) 0.89

Hydrogen cyanide concentrations in the breath of adult cystic fibrosis patients with and without Pseudomonas aeruginosa infection. J Breath Res (2013) 0.89

Nutritional status, perceived body image and eating behaviours in adults with cystic fibrosis. Clin Nutr (2006) 0.88

Chronic rhinovirus infection in an adult with cystic fibrosis. J Clin Microbiol (2013) 0.88

Multi-block poloxamer surfactants suppress aggregation of denatured proteins. Biochim Biophys Acta (2007) 0.85

An investigation of suitable bag materials for the collection and storage of breath samples containing hydrogen cyanide. J Breath Res (2012) 0.85

The changing epidemiology of Burkholderia species infection at an adult cystic fibrosis centre. J Cyst Fibros (2008) 0.84

Efficient production of human beta-defensin 2 (HBD2) in Escherichia coli. Protein Pept Lett (2009) 0.84

Successful treatment of cepacia syndrome with a combination of intravenous cyclosporin, antibiotics and oral corticosteroids. J Cyst Fibros (2012) 0.84

Itraconazole and inhaled fluticasone causing hypothalamic-pituitary-adrenal axis suppression in adults with cystic fibrosis. J Cyst Fibros (2012) 0.83

Treatment of cystic fibrosis associated cutaneous vasculitis with chloroquine. J Cyst Fibros (2010) 0.82

Lack of correlation between O-serotype, bacteriophage susceptibility and genomovar status in the Burkholderia cepacia complex. FEMS Immunol Med Microbiol (2003) 0.82

A therapeutic conundrum: recurrent cystic-fibrosis-related haemoptysis complicated by acute pulmonary embolism. Thorax (2012) 0.81

Recent advances in cross-infection in cystic fibrosis: Burkholderia cepacia complex, Pseudomonas aeruginosa, MRSA and Pandoraea spp. J R Soc Med (2003) 0.80

Lung pathology in response to repeated exposure to Staphylococcus aureus in congenic residual function cystic fibrosis mice does not increase in response to decreased CFTR levels or increased bacterial load. Pathobiology (2004) 0.79

Randomised double blind placebo controlled trial investigating the effect of calcium and vitamin D supplementation on bone mineral density and bone metabolism in adult patients with cystic fibrosis. J Cyst Fibros (2004) 0.79

Is hydrogen cyanide a marker of Burkholderia cepacia complex? J Clin Microbiol (2013) 0.78

Draft Genome Sequence of a Stable Mucoid Strain of Pseudomonas aeruginosa PAO581 with a mucA25 Mutation. Genome Announc (2013) 0.78

Pseudomonas aeruginosa bacteraemia in an adult with cystic fibrosis and acute appendicitis. J Cyst Fibros (2011) 0.77

Antibiotic susceptibility testing in early and chronic respiratory infections with Pseudomonas aeruginosa. J Cyst Fibros (2012) 0.77

Distribution and genomic location of active insertion sequences in the Burkholderia cepacia complex. J Med Microbiol (2006) 0.77

Temperate bacteriophages DK4 and BcepMu from Burkholderia cenocepacia J2315 are identical. FEMS Immunol Med Microbiol (2005) 0.77

Do processing time and storage of sputum influence quantitative bacteriology in bronchiectasis? J Med Microbiol (2010) 0.77

Long-term non-invasive ventilation in cystic fibrosis -- experience over two decades. J Cyst Fibros (2011) 0.77

Pulmonary artery pressure in cystic fibrosis adults: characteristics, clinical correlates and long-term follow-up. J Cyst Fibros (2012) 0.76

Percutaneous gastrostomy feeding in patients with cystic fibrosis. J Pediatr (2006) 0.75

How did the Canterbury earthquakes affect physiotherapists and physiotherapy services? A qualitative study. Physiother Res Int (2014) 0.75

Growth in Stewart's medium is a simple, rapid and inexpensive screening tool for the identification of Burkholderia cepacia complex. J Cyst Fibros (2006) 0.75

Comparing costs of home- versus hospital-based treatment of infections in adults in a specialist cystic fibrosis center. Int J Technol Assess Health Care (2005) 0.75